Close X
Thursday, November 21, 2024
ADVT 
Health

Anti-inflammatory drug may shorten COVID-19 recovery time

Darpan News Desk The Canadian Press, 14 Sep, 2020 08:57 PM
  • Anti-inflammatory drug may shorten COVID-19 recovery time

A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day.

Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The result have not yet been published or reviewed by independent scientists, but the government confirmed that Lilly's statement was accurate.

The study tested baricitinib, a pill that Indianapolis-based Lilly already sells as Olumiant to treat rheumatoid arthritis, the less common form of arthritis that occurs when a mistaken or overreacting immune system attacks joints, causing inflammation. An overactive immune system also can lead to serious problems in coronavirus patients.

All study participants received remdesivir, a Gilead Sciences drug previously shown to reduce the time to recovery, defined as being well enough to leave the hospital, by four days on average. Those who also were given baricitinib recovered one day sooner than those given remdesivir alone, Lilly said.

Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized COVID-19 patients.

If that's approved, Lilly will propose that the drug be sold through usual commercial means. Based on current pricing, the government would pay $105 per patient per day, and for people with private insurance, hospitals would pay about $150 per day, Lilly said. What a patient ends up paying out of pocket depends on many factors.

It would be important to know how many study participants also received steroid drugs, which have been shown in other research to lower the risk of death for severely ill, hospitalized COVID-19 patients, said Dr. Jesse Goodman, former U.S. Food and Drug Administration chief scientist now at Georgetown University who had no role in the study.

Figuring out how to best use the various drugs shown to help “is something we’re going to have to work at,” he said.

MORE Health ARTICLES

COVID-19 measures could disrupt rare polio-like disease

COVID-19 measures could disrupt rare polio-like disease
Health experts once thought 2020 might be the worst year yet for a rare paralyzing disease that has been hitting U.S. children for the past decade.

COVID-19 measures could disrupt rare polio-like disease

Salmonella outbreak linked to U.S. red onions

Salmonella outbreak linked to U.S. red onions
Health authorities are warning consumers in Central and Western Canada to avoid eating red onions imported from the U.S. that have been linked to a salmonella outbreak.

Salmonella outbreak linked to U.S. red onions

Medicare coverage for Alzheimer brain scans in question

Medicare coverage for Alzheimer brain scans in question
A big study to help Medicare officials decide whether to start covering brain scans to check for Alzheimer’s disease missed its goals for curbing health care costs, calling into question whether the pricey tests are worth it.

Medicare coverage for Alzheimer brain scans in question

Rural Canada needs more anesthesia care: doctors

Rural Canada needs more anesthesia care: doctors
Canadians living in rural or remote communities are at risk of poorer health outcomes due to a shortage of anesthesia services, say researchers calling for a national strategy to address inequitable access to care.

Rural Canada needs more anesthesia care: doctors

CFIA investigates unsolicited seed shipments

CFIA investigates unsolicited seed shipments
The Canadian Food Inspection Agency is warning gardeners not to plant "unauthorized seeds" from packages they weren't expecting.

CFIA investigates unsolicited seed shipments

Scientists get closer to blood test for Alzheimer's disease

Scientists get closer to blood test for Alzheimer's disease
An experimental blood test was highly accurate at distinguishing people with Alzheimer’s disease from those without it in several studies, boosting hopes that there soon may be a simple way to help diagnose this most common form of dementia.

Scientists get closer to blood test for Alzheimer's disease